The claim
“Berberine is the natural Ozempic.”
What the evidence actually shows
Berberine is a plant-derived alkaloid that has been examined in human studies for small changes in individual metabolic markers — blood glucose, triglycerides, LDL cholesterol. That is categorically different from the evidence base behind semaglutide.
Ozempic (semaglutide) is a prescription drug with a clearly characterised mechanism of action (GLP-1 receptor agonist), large-scale randomised trials involving thousands of participants, and clinically meaningful effects on body weight and cardiovascular outcomes. The STEP 1 trial, for instance, showed average weight reductions of around 15% over 68 weeks.
Berberine has no comparable evidence. The available studies are typically smaller, more heterogeneous, and methodologically weaker. Effects on body weight where reported are modest fractions of what semaglutide achieves.
Where the claim goes wrong
The “natural Ozempic” framing conflates two fundamentally different categories:
- Mechanism: Semaglutide acts as a GLP-1 receptor agonist with well-characterised pharmacokinetics. Berberine’s metabolic effects are not explained by the same pathway; proposed mechanisms include AMPK activation and gut microbiome modulation.
- Effect size: No berberine trial has approached the weight-loss outcomes observed in semaglutide trials.
- Regulatory category: Semaglutide is a licensed medicine. Berberine is a food supplement. Equating the two is legally problematic in the EU — it implies medicinal efficacy for a non-medicinal product.
EFSA status
No EFSA-approved health claims exist for berberine. Supplements may not be marketed with claims that imply drug-equivalent efficacy.
Verdict
This claim is false. Berberine is not “like Ozempic”. The comparison mixes a plant-based supplement with a pharmaceutical from an entirely different evidence and efficacy class. Presenting berberine as a natural equivalent to a GLP-1 drug misrepresents both the substance and the science.